Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study

Leukemia & Lymphoma
J H LaverJ J Shuster

Abstract

The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage. Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas. This study assessed the overall and event free survival of children with DLCL and determined the effects of cyclophosphamide upon these end-points in a prospective randomized trial. One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991. Patients were randomized to receive or not receive cyclophosphamide: 58 received cyclophosphamide, doxorubicin, vincristine, 6-mercaptopurine (6-MP), and prednisone (ACOP+) and 62 were treated with doxorubicin, vincristine, 6-MP, and prednisone (APO). In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2. Radiation was administered to bulky disease if progression or no response were observed after induction therapy. Planned duration of t...Continue Reading

References

Jun 1, 1991·American Journal of Clinical Pathology·R E HutchisonC W Berard
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E V HvizdalaM D Wharam
Feb 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J BuninS B Murphy
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R E HutchisonS B Murphy
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A ReiterH Riehm
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S B Murphy

❮ Previous
Next ❯

Citations

Jan 14, 2003·Hematological Oncology
Aug 1, 2009·Nature Reviews. Clinical Oncology·John T Sandlund, Joseph H Laver
Jul 16, 2015·Current Hematologic Malignancy Reports·John T Sandlund
Dec 18, 2008·British Journal of Haematology·Jessica HochbergMitchell S Cairo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.